Verification of the Biomarker Candidates for Non-small-cell Lung Cancer Using a Targeted Proteomics Approach

Kim, Yeoun Jin; Sertamo, Katriina; Pierrard, Marie-Aline; Mesmin, Cédric; Kim, Sang Yoon; Schlesser, Marc; Berchem, Guy; Domon, Bruno

doi:10.1021/pr5010828

Cited by 60 publications

(54 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 17 proteins were verified as potent tumor markers, especially, a novel plasma-based biomarker, zyxin (ZYX) was identified as a potential early diagnostic marker for NSCLC [44]. Overall, targeted proteomics is able to yield high probability biomarkers for clinical validation in large patient cohorts and represents a strategy to identify and verify novel different types of diseases [36].…”

Section: Biomarkers In Lung Cancermentioning

confidence: 99%

Quantitative proteomics in lung cancer

Cheung

Juan

2017

J Biomed Sci

View full text Add to dashboard Cite

Lung cancer is the most common cause of cancer-related death worldwide, less than 7% of patients survive 10 years following diagnosis across all stages of lung cancer. Late stage of diagnosis and lack of effective and personalized medicine reflect the need for a better understanding of the mechanisms that underlie lung cancer progression. Quantitative proteomics provides the relative different protein abundance in normal and cancer patients which offers the information for molecular interactions, signaling pathways, and biomarker identification. Here we introduce both theoretical and practical applications in the use of quantitative proteomics approaches, with principles of current technologies and methodologies including gel-based, label free, stable isotope labeling as well as targeted proteomics. Predictive markers of drug resistance, candidate biomarkers for diagnosis, and prognostic markers in lung cancer have also been discovered and analyzed by quantitative proteomic analysis. Moreover, construction of protein networks enables to provide an opportunity to interpret disease pathway and improve our understanding in cancer therapeutic strategies, allowing the discovery of molecular markers and new therapeutic targets for lung cancer.

show abstract

Section: Biomarkers In Lung Cancermentioning

confidence: 99%

Quantitative proteomics in lung cancer

Cheung

Juan

2017

J Biomed Sci

View full text Add to dashboard Cite

show abstract

“…It is now widely appreciated that the initiation and progression of NSCLC is not merely a cell-autonomous process that is confined to the cancer cell itself. Rather, the pathogenic signaling pathways also involve dynamic cross talk between the tumor cells and their microenvironment(13). This bi-directional information flow at the tumor-host interface is particularly relevant in the metastatic setting, where extensive tissue remodeling and tumor adaptation occur.…”

Section: Introductionmentioning

confidence: 99%

Quantitative Secretomic Analysis Identifies Extracellular Protein Factors That Modulate the Metastatic Phenotype of Non-Small Cell Lung Cancer

Huffman

Chu

et al. 2016

J. Proteome Res.

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer-related deaths for men and women in the United States, with non-small cell lung cancer (NSCLC) representing 85% of all diagnoses. Late stage detection, metastatic disease and lack of actionable biomarkers contribute to the high mortality rate. Proteins in the extracellular space are known to be critically involved in regulating every stage of the pathogenesis of lung cancer. To investigate the mechanism by which secreted proteins contribute to the pathogenesis of NSCLC, we performed quantitative secretomic analysis of two isogenic NSCLC cell lines (NCI-H1993 and NCI-H2073) and an immortalized human bronchial epithelial cell line (HBEC3-KT) as control. H1993 is derived from a chemo-naïve metastatic tumor while H2073 was derived from the primary tumor after etoposide/cisplatin therapy. From the conditioned media of these three cell lines, we identified and quantified 2713 proteins. Gene Ontology (GO) analysis indicates that a number of proteins overexpressed in H1993 media are involved in biological processes related to cancer metastasis, including cell motion, cell-cell adhesion and cell migration. RNA interference (RNAi)-mediated knock down of a number of these proteins, including SULT2B1, CEACAM5, SPRR3, AGR2, S100P and S100A14, leads to dramatically reduced migration of these cells. In addition, meta-analysis of survival data indicates NSCLC patients whose tumors express higher levels of several of these secreted proteins, including SULT2B1, CEACAM5, SPRR3, S100P and S100A14, have a worse prognosis. Collectively, our results provide a potential molecular link between deregulated secretome and NSCLC cell migration/metastasis. In addition, the identification of these aberrantly secreted proteins might facilitate the development of biomarkers for early detection of this devastating disease.

show abstract

“…In a study conducted by Kim et al multiplexed liquid chromatography‐selected reaction monitoring (LC‐SRM) was applied to screen 72 plasma samples from NSCLC patients from early to late stage disease . Seventeen candidate NSCLC biomarkers were identified with at least a 2‐fold change in NSCLC compared to healthy controls and further evaluated by ELISA ( n = 144 samples).…”

Section: Systematic Reviewmentioning

confidence: 99%

“…Seventeen candidate NSCLC biomarkers were identified with at least a 2‐fold change in NSCLC compared to healthy controls and further evaluated by ELISA ( n = 144 samples). Among them, zyxin demonstrated the highest specificity towards NSCLC (AUC = 0.96) and was proposed as an early diagnostic biomarker for detection of NSCLC …”

Section: Systematic Reviewmentioning

confidence: 99%

“…However, as pointed out by Taguchi et al, it appears that the accuracy of the prediction by VeriStrat is insufficient to guide treatment, and its value in prediction of the drug response was until now not demonstrated convincingly 65. In a study conducted by Kim et al multiplexed liquid chromatography-selected reaction monitoring (LC-SRM) was applied to screen 72 plasma samples from NSCLC patients from early to late stage disease 70. Seventeen candidate NSCLC biomarkers were identified with at least a 2-fold change in NSCLC compared to healthy controls and further evaluated by ELISA (n = 144 samples).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Proteomics biomarkers for solid tumors: Current status and future prospects

Belczacka

Latosinska

Metzger

et al. 2018

Mass Spectrometry Reviews

View full text Add to dashboard Cite

Cancer is a heterogeneous multifactorial disease, which continues to be one of the main causes of death worldwide. Despite the extensive efforts for establishing accurate diagnostic assays and efficient therapeutic schemes, disease prevalence is on the rise, in part, however, also due to improved early detection. For years, studies were focused on genomics and transcriptomics, aiming at the discovery of new tests with diagnostic or prognostic potential. However, cancer phenotypic characteristics seem most likely to be a direct reflection of changes in protein metabolism and function, which are also the targets of most drugs. Investigations at the protein level are therefore advantageous particularly in the case of in-depth characterization of tumor progression and invasiveness. Innovative high-throughput proteomic technologies are available to accurately evaluate cancer formation and progression and to investigate the functional role of key proteins in cancer. Employing these new highly sensitive proteomic technologies, cancer biomarkers may be detectable that contribute to diagnosis and guide curative treatment when still possible. In this review, the recent advances in proteomic biomarker research in cancer are outlined, with special emphasis placed on the identification of diagnostic and prognostic biomarkers for solid tumors. In view of the increasing number of screening programs and clinical trials investigating new treatment options, we discuss the molecular connections of the biomarkers as well as their potential as clinically useful tools for diagnosis, risk stratification and therapy monitoring of solid tumors.

show abstract

Verification of the Biomarker Candidates for Non-small-cell Lung Cancer Using a Targeted Proteomics Approach

Cited by 60 publications

References 30 publications

Quantitative proteomics in lung cancer

Quantitative proteomics in lung cancer

Quantitative Secretomic Analysis Identifies Extracellular Protein Factors That Modulate the Metastatic Phenotype of Non-Small Cell Lung Cancer

Proteomics biomarkers for solid tumors: Current status and future prospects

Contact Info

Product

Resources

About